SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Counsyl, a genetic screening and counseling services company, today announced that more than one million of the company's three premium genetic screens have been performed. By offering quick, accurate results with Foresight™ Carrier Screen, Prelude™ Prenatal Screen, and Reliant™ Cancer Screen, Counsyl has provided important information to people and families about reproductive health and hereditary cancer risk so they can make informed choices and plan for the future. This significant milestone illustrates the increasing recognition of the critical value of genetic screening in women's health.
"As a doctor, I'm thrilled by this achievement because it means that patients have received crucial information that can help guide them in important decisions for themselves and their families," said Dr. James Goldberg, chief medical officer at Counsyl. "While we continue to make incredible progress, we have a long way to go until women and their families are aware of the availability and utility of genetic screening, but I am confident that we will soon make this a routine part of patient care."
Counsyl's genetic screens and counseling services fulfill specific, personalized roles in patients' healthcare needs. While each screen is tailored for a unique patient segment, Counsyl Complete™, our provider practice workflow solution, provides pre-test education, billing support, clear results reporting and on-demand genetic counseling.
Counsyl's groundbreaking Foresight™ Carrier Screen was developed for couples who are planning to become pregnant and has identified more than 2,500 couples whose children have a significantly increased chance of being affected by an inherited disease. In fact, 86% of these couples would have been missed under conventional screening guidelines.
Similarly, Counsyl's Prelude™ Prenatal Screen is offered to pregnant women who want to know their baby's chance of having a chromosomal condition such as Down syndrome. This screen, which has one of the lowest no-call rates in the industry of 0.1%, has helped successfully identify nearly 3,000 pregnancies at risk for a serious chromosomal abnormality, and provides meaningful insights for patient care. Moreover, by providers choosing to use Counsyl Prelude instead of first trimester screening, we've helped patients avoid nearly 7,500 false positives for Down syndrome, substantially avoiding unnecessary invasive procedures and reducing patient anxiety.
In addition to reproductive screening, Counsyl offers the Reliant™ Cancer Screen, which is available to women interested in confirming whether they have an increased risk for hereditary cancers such as breast, ovarian, colon and pancreatic. To date, Counsyl has helped more than 3,200 patients determine that they have an increased risk of developing cancer, allowing them to pursue additional cancer screening or preventative measures.
"What an incredible milestone! Thousands of physicians and hundreds of thousands of patients have chosen Counsyl at crucial life moments before and during pregnancy, and for cancer risk assessment. It's the highest form of recognition we can imagine: our patients have trusted Counsyl now over a million times," said Ramji Srinivasan, chief executive officer at Counsyl.
Counsyl was founded in 2007. Whether it's starting a family or evaluating one's risk for cancer, Counsyl's genetic screens provide patients in the United States with actionable information about a range of genetic conditions so they can make critical and timely health decisions. Counsyl has performed more than one million genetic screens, continues to serve thousands of healthcare providers and has provided more than 75,000 genetic counseling sessions. For more information, visit www.counsyl.com.